- Home
- IKNA vs ASRT Comparison
IKNA vs ASRT Comparison
Compare IKNA & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- ASRT
- Stock Information
- Founded
- IKNA 2016
- ASRT 1995
- Country
- IKNA United States
- ASRT United States
- Employees
- IKNA N/A
- ASRT N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- IKNA Health Care
- ASRT Health Care
- Exchange
- IKNA Nasdaq
- ASRT Nasdaq
- Market Cap
- IKNA 52.1M
- ASRT 57.9M
- IPO Year
- IKNA 2021
- ASRT 1997
- Fundamental
- Price
- IKNA $1.19
- ASRT $0.66
- Analyst Decision
- IKNA Buy
- ASRT Strong Buy
- Analyst Count
- IKNA 2
- ASRT 3
- Target Price
- IKNA $3.00
- ASRT $3.08
- AVG Volume (30 Days)
- IKNA 109.0K
- ASRT 284.6K
- Earning Date
- IKNA 05-08-2025
- ASRT 05-12-2025
- Dividend Yield
- IKNA N/A
- ASRT N/A
- EPS Growth
- IKNA N/A
- ASRT N/A
- EPS
- IKNA N/A
- ASRT N/A
- Revenue
- IKNA N/A
- ASRT $119,001,000.00
- Revenue This Year
- IKNA N/A
- ASRT N/A
- Revenue Next Year
- IKNA N/A
- ASRT $11.71
- P/E Ratio
- IKNA N/A
- ASRT N/A
- Revenue Growth
- IKNA N/A
- ASRT N/A
- 52 Week Low
- IKNA $0.97
- ASRT $0.51
- 52 Week High
- IKNA $1.94
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- IKNA 53.94
- ASRT 50.57
- Support Level
- IKNA $1.10
- ASRT $0.67
- Resistance Level
- IKNA $1.20
- ASRT $0.71
- Average True Range (ATR)
- IKNA 0.08
- ASRT 0.04
- MACD
- IKNA 0.01
- ASRT 0.00
- Stochastic Oscillator
- IKNA 74.26
- ASRT 52.69
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.